Remove Events Remove Radiograph Remove Radiographer
article thumbnail

FDA warns against use of Hologic breast care device after nearly 200 adverse events

Radiology Business

The alert pertains to the BioZorb and BioZorb LP markers, implanted in soft tissue to indicate the site for radiographic procedures.

article thumbnail

Dozens of injuries trigger FDA recall of over 50,000 implantable tissue marking devices

Health Imaging

The Class I recall, which is the most serious recall the FDA issues, comes after numerous adverse events and complications linked to the radiographic markers were reported.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

International Day of Radiology to be held on November 8

AuntMinnie

On November 8, radiologists, radiographers, and radiological technologists will mark the tenth International Day of Radiology (IDoR 2023). Keep up with the latest details about the International Day of Radiology via its Facebook page.

article thumbnail

Phase 3 Study Shows Viability of 177Lu-PSMA-617 for Taxane-Naïve Metastatic Castration-Resistant Prostate Cancer

Diagnostic Imaging

The use of 177Lu-PSMA-617 was associated with a significantly longer radiographic progression-free survival and a 12 percent lower rate of grade 3 or higher adverse events in comparison to a change of ARPI therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).

article thumbnail

Road to RSNA 2023: AI Preview

AuntMinnie

We’re once again providing a modality-by-modality overview of select scientific presentations to serve as your guide to events at McCormick Place. The AI Showcase is also the home of the AI Theater, which will host the AI Challenge Recognition Event at 4 p.m. Interested in a hands-on educational AI experience suitable for beginners?

article thumbnail

SNMMI: Lu-177 PSMA-617 shines for taxane-naive prostate cancer

AuntMinnie

Radiographic progression-free survival (rPFS) was the primary endpoint of the study, while overall survival was the key secondary endpoint. The most common groups of any-grade treatment-emergent adverse events in the Lu-177 PSMA-617 group were dry mouth and myelosuppression, resulting in anemia, thrombocytopenia, and neutropenia.

article thumbnail

FDA recalls Hologic's BioZorb markers

AuntMinnie

Food and Drug Administration (FDA) has issued a recall of Hologics BioZorb 3D bioabsorbable radiographic markers, with 252 injuries reported to date. Monitor patients who have an implanted BioZorb Marker for signs of any adverse events, the FDA advised, in a December 18 notification.